Indonesia - indonesisk - Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

aventis pharma - indonesia - rifapentine - tablet salut selaput - 150.00 mg

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (united states) - rifapentine - oral tablet - 150mg

Filippinene - engelsk - FDA (Food And Drug Administration)

njt enterprmrses - rifapentine - film-coated tablet - 150 mg

Filippinene - engelsk - FDA (Food And Drug Administration)

sanofi-aventis philippines, inc.; distributor: sanofi-aventis philippines, inc. - priftin - film-coated tablet - 150 mg

Den europeiske union - nederlandsk - EMA (European Medicines Agency)

janssen-cilag international nv - simeprevir - hepatitis c, chronisch - antivirale middelen voor systemisch gebruik - olysio is geïndiceerd in combinatie met andere geneesmiddelen voor de behandeling van chronische hepatitis c (chc) bij volwassen patiënten. voor hepatitis-c-virus (hcv) genotype specifieke activiteit.

Singapore - engelsk - HSA (Health Sciences Authority)

pfizer private limited - (active filler coat) sirolimus @ 100% - tablet, sugar coated - 2.0 mg - (active filler coat) sirolimus @ 100% 2.0 mg

Singapore - engelsk - HSA (Health Sciences Authority)

pfizer private limited - sirolimus - solution - 1 mg/ml - sirolimus 1 mg/ml

Singapore - engelsk - HSA (Health Sciences Authority)

pfizer private limited - (active filler coat) sirolimus @ 100% - tablet, sugar coated - 1.00 mg - (active filler coat) sirolimus @ 100% 1.00 mg

Den europeiske union - engelsk - EMA (European Medicines Agency)

janssen-cilag international nv - simeprevir - hepatitis c, chronic - antivirals for systemic use - olysio is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adult patients.for hepatitis c virus (hcv) genotype specific activity.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

astrazeneca limited - olaparib 50mg - capsule - 50 mg - active: olaparib 50mg excipient: gellan gum hypromellose lauroyl macrogol-32 glycerides iron oxide black potassium acetate shellac titanium dioxide - lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed brca-mutated (germline or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) after platinum-based chemotherapy. prior treatment must have included at least 2 courses of platinum-based regimens.